Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BioNTech SE

< Previous 1 2 Next >
BioNTech to Acquire Biotheus to Boost Oncology Strategy
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Host Innovation Series R&D Day on November 14, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Planned Retirement of Sean Marett
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.